Philip Wiebkin
- Pharmacology top 2%
- Pharmacogenetics and Drug Metabolism 8
- Drug-Induced Hepatotoxicity and Protection 4
- Hepatology top 10%
- Liver physiology and pathology 2
- Biochemistry top 10%
- Eicosanoids and Hypertension Pharmacology 2
-
- Carcinogens and Genotoxicity Assessment 5
-
- Alcohol Consumption and Health Effects 3
-
- Metabolomics and Mass Spectrometry Studies 2
-
- Drug Transport and Resistance Mechanisms 2
- Co-authors
- James Winfred BridgesJeffrey R. FryCarol JonesRussell A. ProughPeter BellemannDaniel S. LongneckerBill D. RoebuckJohn Y. Kao
- Cited by
- PharmacologyHepatologyBiochemistry
- Journals
- Analytical Biochemistry (1 paper)Biochemical Journal (1 paper)Biochemical Pharmacology (8 papers)
- Partner nations
- United KingdomUnited States
In The Last Decade
Philip Wiebkin
23 papers receiving 472 citations
Peers
Comparison fields: 5 of 86
- Pharmacology 210
- Hepatology 54
- Biochemistry 47
- Cancer Research 81
- Health, Toxicology and Mutagenesis 65
Countries citing papers authored by Philip Wiebkin
This map shows the geographic impact of Philip Wiebkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Wiebkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Wiebkin more than expected).
Fields of papers citing papers by Philip Wiebkin
This network shows the impact of papers produced by Philip Wiebkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Wiebkin. The network helps show where Philip Wiebkin may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Philip Wiebkin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1995 | 17 | |
| 2 | 1989 | 3 | |
| 3 | 1988 | 1 | |
| 4 | 1985 | 15 | |
| 5 | 1985 | 14 | |
| 6 | Experimental carcinogenesis in the pancreas. | 1984 | 43 |
| 7 | 1984 | 11 | |
| 8 | 1984 | 7 | |
| 9 | 1984 | 2 | |
| 10 | 1982 | 3 | |
| 11 | 1982 | 17 | |
| 12 | Metabolism of procarbazine [N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide HCl]. | 1981 | 4 |
| 13 | 1980 | 32 | |
| 14 | 1979 | 22 | |
| 15 | 1979 | 6 | |
| 16 | 1979 | 2 | |
| 17 | 1978 | 39 | |
| 18 | 1978 | 45 | |
| 19 | 1976 | 124 | |
| 20 | 1976 | 45 |
About Philip Wiebkin
Philip Wiebkin is a scholar working on Pharmacology, Biochemistry and Cancer Research, having authored 23 papers that have together received 503 indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (8 papers), Carcinogens and Genotoxicity Assessment (5 papers), Drug-Induced Hepatotoxicity and Protection (4 papers), Alcohol Consumption and Health Effects (3 papers), Metabolomics and Mass Spectrometry Studies (2 papers), Drug Transport and Resistance Mechanisms (2 papers), Liver physiology and pathology (2 papers) and Eicosanoids and Hypertension Pharmacology (2 papers). The work is most often cited by research in Pharmacology (210 citations), Hepatology (54 citations) and Biochemistry (47 citations). Philip Wiebkin has collaborated with scholars based in United Kingdom and United States. Frequent co-authors include James Winfred Bridges, Jeffrey R. Fry, Carol Jones, Russell A. Prough, Peter Bellemann, Daniel S. Longnecker, Bill D. Roebuck, John Y. Kao, Douglas W. Hoffman and Leonard P. Rybak. Their work appears in journals such as Analytical Biochemistry, Biochemical Journal and Biochemical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.